1	Early recovery of leukocyte subsets is associated with progression-free survival in patients with
2	inoperable stage III NSCLC after multimodal treatment: a prospective explorative study
3	
4	Thomas P. Hofer ¹ , Alexander E. Nieto ² , Lukas Käsmann ^{2,3,4} , Carolyn J. Pelikan ¹ , Julian Taugner ² , Saloni
5	Mathur ¹ , Chukwuka Eze ² , Claus Belka ^{2,3,4} , Farkhad Manapov ^{2,3,4,*} , Elfriede Nößner ^{1,*}
6	
7	¹ Helmholtz Zentrum München, Immunoanalytics – Tissue Control of Immunocytes, Munich,
8	Germany; ² Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany;
9	3 German Center for Lung Research (DZL), partner site Munich, Germany; 4 German Cancer
10	Consortium (DKTK), partner site Munich, Germany; * these authors contributed equally to this work
11	
12	Corresponding author : Thomas P. Hofer, <u>thomas.hofer@helmholtz-munich.de</u> , Helmholtz Center
13	Munich, Feodor-Lynen-Str. 21, D-81377 Munich
14	
15	Short title: Radio-Immune-Lung-Study-NSCLC
16	
17	Highlights
18	• Early increase within 3 weeks after thoracic radiation therapy (TRT) of CD8+ T cells is
19	associated with favorable progression free survival (PFS).
20	• Low standard deviation in IL-6 plasma concentration in consecutive measurements after TRT
21	is associated with favorable PFS.
22	• Absolute lymphocyte counts at treatment begin had no predictive value for treatment
23 24	outcome.
25	Funding statement: none
26	
27	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

28 Key words

- 29 Non-small cell lung cancer, linear discriminant analysis, peripheral blood markers, area under curve
- 30 analysis, immune checkpoint therapy, progression-free survival, overall survival, CD4+ T cells, CD8+ T
- 31 cells, NK cells, B cells, Neutrophils, Eosinophils

- 33 Abbrevations
- 34 AB Antibody
- 35 ALC Absolute Lymphocyte Count
- 36 ASP Antibody Staining Panel
- 37 cCRT concurrent Chemoradiotherapy
- 38 Durva Durvalumab
- 39 FCM Flow Cytometry
- 40 FCS Fetal Calf Serum
- 41 FL Fluorochrome
- 42 Gy Gray
- 43 ICI Immune Checkpoint Inhibition
- 44 IQR Inter Quantile Range
- 45 LDA Linear Discriminant Analysis
- 46 LQR Lower Quartile Range
- 47 mo Month(s)
- 48 Nivo Nivolumab
- 49 NLR Neutrophil-Lymphocyte-Ratio
- 50 NSCLC Non-small cell lung cancer
- 51 OS Overall Survival
- 52 PFS Progression-free Survival
- 53 RT Radiation Therapy
- 54 TRT Thoracic Radiotherapy
- 55 UQR Upper Quantile Range
- 56 y Year(s)
- 57

58	Abstract
50	

59

60 Background

61 We explored the dynamic changes of major leukocyte subsets during definitive treatment of patients

62 with inoperable stage III NSCLC lung cancer and correlated it to survival to identify subpopulations

63 associated with maximal patient benefit.

64

65 Methods

66 We analyzed peripheral blood of 20 patients, either treated with thoracic radiotherapy (RT),

67 concurrent chemo-radiotherapy (cCRT), or cCRT with additional immune-checkpoint inhibition

therapy. Blood samples were collected at 9 timepoints before, during, and up to 1 year post

69 treatment and analyzed by multi-color flow cytometry. Statistical analysis was conducted for

70 leukocyte subpopulations, IL-6, progression-free survival (PFS) and overall survival (OS).

71

72 Results

73 Increase of absolute lymphocyte counts (ALC) after the end of RT until 6 months thereafter was a

74 predictor of PFS. Baseline lymphocyte counts showed no significant correlation to PFS or OS. Early

recovery of absolute counts (AC) at 3 weeks after RT, total CD3+ T-cells, and CD8+ cytotoxic T-cells

distinguished those patients with favorable PFS (≥12 months) from all other patients. Discriminant

analysis identified B-cells, neutrophil-lymphocyte-ratio (NLR), CD4+ T-helper-cells, and NK-cells as

78 predictors of favorable PFS. High variability in IL-6 plasma concentration of consecutive

79 measurements within 6 months after the end of RT correlated negatively with PFS.

80

81 Conclusion

82 Our results suggest that two parameters commonly assessed in clinical routine, can be used to

83 predict patient outcome. These are: early increase in CD8+ T-cell lymphocyte-count and variability in

- 84 IL-6 plasma concentration, that are correlated to patients with favorable, respectively, poor outcome
- 85 after definitive therapy independent of treatment regimen.

86

87 Key words

- 88 Non-small cell lung cancer, linear discriminant analysis, peripheral blood markers, area under curve
- analysis, immune checkpoint therapy, progression-free survival, overall survival, CD4+ T cells, CD8+ T
- 90 cells, NK cells, B cells, Neutrophils, Eosinophils
- 91

92 Background

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers, and prognosis
 remains poor with a low 5-year survival rate, only up to 36% of patients with an advanced stage

95 experiencing sustained clinical benefit from therapy [1]. Treatment advances were achieved by

96 introducing immune checkpoint therapy (ICI) as monotherapy or in addition to chemo-radiotherapy

97 [2, 3].

98 There is a medical need to not only find more effective therapies but also to identify those patients

99 who are likely to benefit from added ICI or should be spared the side effects if ICI is ineffective [4].

100 Ongoing efforts are being made to identify suitable biomarkers to predict benefit or non-response,

101 preferably obtained from easily and repeatedly accessible biomaterial like venous peripheral blood.

102

103 In this prospective single-center study we aimed to explore whether the dynamics of defined

104 lymphocyte subsets might be suitable to predict survival. We performed immune monitoring on

105 patients who underwent therapy for inoperable stage III NSCLC. We prospectively report on

106 characteristics of absolute T-cell counts (total CD3+ T-cells, CD3+CD4+, and CD3+CD8+ T-cells), B-

107 cells, NK-cells, neutrophils, thrombocytes, and IL-6 plasma levels regarding patient treatment and

108 outcome (progression free survival, PFS, and overall survival, OS).

109

110 Material and Methods

- 111 Patients, Controls, Blood Sampling, Treatment
- 112 Blood samples from patients with unresectable stage III non-small cell lung cancer (NSCLC; 8th TNM
- 113 staging system) without distant metastases were obtained before as well as during treatment and
- follow-up at the Clinic for Radiation Oncology of the LMU University Hospital, Munich. All patients
- 115 were included in this study on a voluntary basis and provided written informed consent. The study
- 116 was approved by the Human Ethics Committee of the Ludwig-Maximilians-University of Munich
- reference no. 17-632 and conducted in accordance with the Declaration of Helsinki.
- 118 Twenty patients (17 male, 3 female), first diagnosed with a median age of 65.5 years (range 34 to 79)

119 were enrolled in this study (Tab. 1; Fig. S1).

120

121 Tab. 1: Characteristics of patients with NSCLC and healthy controls

123	Patients	n=20
124	Age (mean SD) (years)	62.5 ± 13.75
125	(median / range) (years)	65.5 / 34-79
126	Sex (male / female)	17 / 3
127	Therapy (RT, cCRT, cCRT-ICI, salvage therapy)	2 / 12 / 7 / 3
128	Adenocarcinoma	11
129	Squamous cell carcinoma	8
130	Undiff. NSCLC	1
131	Distant metastasis	8
132	Local remission	9
133	Death	7
134	Smokers (none / active / ex)	1/7/12
135	Smoking history > 50 pack years	8
136		
137	Healthy Controls	n= 9
138	Age (mean SD) (years)	35 ± 13.74
139	(median / range) (years)	30 / 24-59
140	Sex (male / female)	1/8
141	Smokers (none / active / ex)	8/1/0
142		

144	Blood samples were collected	before onset of	therapy (A.1 at week 0),	twice during (A.2 and A.3 at
-----	------------------------------	-----------------	--------------------------	------------------------------

145 week 2 and 5, respectively) and at the end of radiotherapy (RTend at week 7), and during follow up

146 (C.1 to C.5 at week 10, 20, 35, 48, and 60) (Fig. S1).

147 The controls constituted of 9 apparently healthy individuals (CTRL) with a median age of 30y (range

- 148 24 to 59) at the timepoints of blood sampling; 1 male and 8 females (Fig. 1, Tab. 1). Samples were
- 149 processed and analyzed simultaneously and identically to the patient samples.
- 150

151 Patient treatment modality was concluded at the discretion of the treating physician based on clinical

standards and following multidisciplinary tumor board discussion. Two patients received RT alone, 18

- 153 patients were treated with platinum-based concurrent cCRT, and 7 patients received additional ICI
- either concurrently (nivolumab) or sequentially (durvalumab). More detail is provided in Fig. S1.

155

156 Leukocyte Phenotyping

157 Blood was collected using 3K-EDTA S-Monovette tubes (Sarstedt, Germany) and samples were

analyzed within 3 hours. Using 100 µl of whole blood, erythrocytes were lysed, cells were surface-

stained, spiked with counting beads and analyzed on a BD LSRII flow cytometer. Details on sample

160 preparation, staining and gating strategy, cell type identification are given in the supplements (Fig.

161 S2, Tab. S1).

162 Neutrophil and lymphocyte counts used to calculate Neutrophil-Lymphocyte-Ratio (NLR), eosinophil

163 counts, and IL-6 plasma levels were obtained from clinical routine blood testing (clinical chemistry).

164

165 Analysis of immunocyte population dynamics and variation of IL-6 plasma concentration

166 To describe the dynamic changes in absolute cell counts during the period after treatment end

- 167 (RTend), we calculated the area under the curve (AUC) of consecutive blood sampling timepoints
- 168 from RTend-C.3 (6 mo after treatment end). Low or high AUC reflect higher or lower AC in this
- 169 period.

170 For analysis of variation of IL-6 concentration during RTend-C.3. standard deviation
--

- 171 values at three consecutive timepoints after RTend were calculated and stratified according to
- groups with poor (<6 mo), intermediate (\geq 6<12 mo), and favorable (\geq 12 mo) PFS.
- 173

174 Statistical analysis

- 175 This study was designed as a discovery study with the intention of generating hypotheses. Statistical
- 176 tests were Student's t-test, Kruskal Wallis test, Log-rank (Mantel-Cox), Fisher's Exact test, and Log-
- 177 Rank for trend. Differences were considered significant with p<0.05. For multivariate discriminant
- analysis (MDA), and heatmap visualization, R statistical software V4.2.1 and the packages
- 179 ComplexHeatmap V2.12.1, Dplyr V1.0.10, Plyr V1.8.7, missMDA V1.18, Openxlsx V4.2.5, Stats V4.3.0
- 180 and Tidyverse 1.3.2 were used.
- 181 For MDA, we used the ggord package from Marcus W. Beck (2017). ggord: Ordination Plots with
- 182 ggplot2. R package version 1.0.0 <u>https://zenodo.org/badge/latestdoi/35334615</u>. For generating
- graphs and Kaplan-Meier curves, GraphPad Prism V9, and for MANOVA analysis Past V4.11 [5] were
- 184 used.

185

186 Results

187 No prognostic value of ALC for PFS or OS at any single timepoint before, during and after treatment

188 Baseline ALC were highly heterogenous in the NSCLC patient cohort (n=20) with a higher median of

189 1.57 (range 4.65-0.58) Gcells/L of ALC compared to the controls (n=9, median 1.29, range 2.69-0.80

- 190 Gcells/L). All patients experienced moderate to severe lymphocytopenia (assessed per the Common
- 191 Terminology Criteria for Adverse Events v5.0) during RT/cCRT with median ALC of 0.75 (range 1.80-
- 192 0.21), 0.61 (range 4.36-0.15), and 0.46 (range 2.57-0.21) Gcells/L at timepoint A.2, A.3, and RTend,
- respectively (grey area in Fig.1). ALC recovered after RTend reaching median values of 1.10 (range

- 194 3.85-0.09) Gcells/L at C.1 (3 wks after RTend), 1.09 (range 6.04-0.09) Gcells/L at C.2 (3 mo after
- 195 RTend), 1.21 (range 4.00-0.08) Gcells/L at C.3 (6 mo after RTend), 1.72 (range 2.99-0.77) Gcells/L at
- 196 C.4 (10 mo after RTend), and 1.19 (range 5.47-0.54) Gcells/L at C.5 (13 mo after RTend). The recovery
- 197 varied across patients, some with poor others with good increase in cell counts.



Fig. 1 ALC in NSCLC patients' peripheral blood (n=20) before (A.1), during (A.2, A.3, RTend), and up to 1 y (C.1-C.5) after treatment. Grey violin represents ALC of CRTL (n=9). Each dot represents an individual, color codes the PFS group of the patients. Grey area represents the interval of radio- (RT) or chemoradiotherapy (cCRT), color-coded lines connect the median of ALC of each PFS group at the different timepoints. The bold dashed line in the violins indicate median, light dotted lines the lower and upper quartile. Student'st test, * p<0.05, ** p<0.01, ***p<0.001 compared to A.1; ⊕ p<0.05 compared to preceding timepoint.</p>

205

206 Patients were stratified according to PFS after RTend, with poor PFS<6 mo indicated by purple dots,

intermediate PFS≥6<12 mo shown as black dots, and favorable PFS≥12 mo depicted as green dots.

208 Patients with favorable PFS had on average an early increase in ALC within 3 weeks after RTend (C.1),

209 peaking at timepoint C.2 (14 weeks after RTend) and return to a median ALC comparable to the CTRL.

- 210 Patients with poor and intermediate PFS had a delayed increase in ALC with a peak in cell counts at
- 211 C.4 (40 weeks). Although these data indicated that an early recovery of ALC may be beneficial with

- regards to PFS, there was high ALC heterogeneity within the PFS groups: 3 of 6 patients in the
- 213 favorable PFS group had no early ALC peak at 14 weeks.
- 214
- 215 Dynamics of leukocyte subpopulations after RT
- Favorable PFS group (≥12 mo) showed significant increase in AC from RTend to C.1 for lymphocytes,
- total T-cells, and CD8+ T-cells. For the other PFS groups, lymphocytes and CD4+ T-cells did not
- 218 increase, or the increase occurred later (between RTend and C.3) (Fig. 2, Fig. S4). This was observed
- 219 for total lymphocytes as well as total CD3+ T-cells and CD8+ T-cells, but not for CD4+ T-cells (for
- 220 medians and p-values see Tab S1). This implies that an early increase of lymphocytes, total CD3+ T-
- cells, or CD8+ T-cells within 3 or 14 weeks after RTend (C.1, or C.2) identifies patients with a
- favorable progression-free survival-time ≥12 mo.



Fig. 2 Absolute cell counts of lymphocytes, CD3+T-cells, CD4+T-cells, and CD8+T-cells (analyzed with flow cytometry) at
 timepoints RTend, C.1, C.2, and C.3 within the different PFS groups (PFS<6 mo (red), PFS ≥6<12 mo (grey), PFS ≥12 mo
 (green)). Cell counts were derived from flow cytometry (gating strategy in Fig. S2), each dot represents an individual.

227 Comparison was performed across timepoints within each PFS groups, bold dashed line in the violins indicate median, light

dotted lines lower and upper quartile. Student's t-test, * p<0.05, ** p<0.01.

229

230 An increase in neutrophil count with inadequate T-cell and no NK-cell expansion after RTend was 231 observed in the poor prognostic group (Fig. 2, Fig. S4). The intermediate and favorable prognostic 232 groups showed peripheral NK-cell increase after RTend (Fig. S4) while the poor prognostic group did 233 not (median value for intermediate group at RTend 0.014, at C.1 0.040, at C.2 0.132, at C.3 0.257 234 Gcells/L; RTend-C.1 p=0.094, RTend-C.2 p=0.011, RTend-C.3 p=0.015; median value for favorable 235 group see Tab. S2). The favorable prognostic group showed increaseF after RTend of CD8+ T-cells 236 (median value for intermediate group at RTend 0.14, at C.1 0.51, at C.2 0.42, at C.3 0.73 Gcells/L; 237 RTend-C.1 p=0.0596, RTend-C.2 p=0.053, RTend-C.3 p=0.031; median value for favorable group Tab. 238 S2). 239 All patients experienced leukocytopenia following RT or cCRT (Fig. 1). We hypothesized that the 240 change of lymphocytes within the first 6 mo after end of therapy might be most meaningful for 241 therapy response as the immune system reconstitutes and can react to neoantigens released from 242 destroyed tumor cells. To picture the dynamic processes during this phase between RTend-C.3 (6 243 mo), AUC of the absolute cell counts of the major leukocyte subpopulations was calculated and 244 compared to patient outcome.

Higher AUC for the period between RTend-C.3 reflect a more pronounced increase of absolute cell
counts after therapy. Patients in the poor PFS group (PFS<6 mo) compared to the favorable
prognostic group (PFS≥12 mo) had significantly lower AUC for CD3+ T-cells (p=0.0053), CD4+ T-cells
(p=0.0026), and NK-cells (p=0.0008) (Fig. 3). AUC of CD8+ T-cells, B-cells, eosinophils, and NLR were
not different between the poor and good prognostic groups.



250

Fig. 3 Standardized AUC (Z-score) for the interval RTend-C.3 of leukocyte subpopulations stratified according PFS groups
(PFS<6 mo (red), PFS ≥6<12 mo (grey), PFS ≥12 mo (green)). Cell counts were derived from flow cytometry (gating strategy
in Fig. S2), neutrophil, and eosinophil counts were determined by clinical chemistry routine lab (clCh). Each dot represents
the value of an individual, bold dashed line in the violins indicate median, light dotted lines lower and upper quartile.
Student's T test, * p<0.05, ** p<0.01, ***<0.001.

256

257 Unsupervised clustering reveals longer PFS for patients receiving ICI

258 Normalized lymphocyte parameters were clustered by unsupervised hierarchical clustering. PFS,

- treatment regimen, local relapse, distant metastases were annotated to, but were not included in
- 260 the clustering. The result (Fig. 4) identified two clusters: on the right side were patients with low AUC
- for all cell types, except NLR (assigned "cold" group) (9 of 19 patients). Only 1 patient (1 of 9 patients)
- within this group had received ICI. Most patients (7 of 9patients) in this "cold" lymphocyte-reduced

- 263 group had developed local tumor recurrence (LR) after definitive therapy and only 2 (of 9) belonged
- to the favorable group (PFS≥12 mo). Patients clustering to the left (10 of 19 patients) had higher AUC
- 265 (RTend-C.3) for all leukocyte subpopulations except NLR (assigned "hot" group). Six of the patients of
- the "hot" group had been treated with ICI (6 of 10), only 2 (of 10) had experienced LR and most
- 267 belonged to the favorable PFS group (7 of 19).



²⁶⁸

- 269 Fig. 4 Heatmap of unsupervised clustering of AUC (RTend-C.3) of leukocyte subpopulations, every column represents a
- 270 patient, PFS (<6mo, \geq 6 <12mo, and \geq 12mo), treatment regime and recurrence (LR, local recurrence; DM, distant
- 271 metastases) (AUCs) in patients (n=19). Bold vertical line separates a "hot" group (higher AUC) and a left "cold" group (lower
- 272 AUC).
- 273

275	Fisher's Exact Testing "cold" or "hot" group against good or poor PFS (≥12 mo 10 patients; and <12
276	mo, 9 patients, respectively) revealed a statistically non-significant value of p=0.069. The Odds ratio
277	(95% CI) was 7.17 (0.752, 113.47).
278	
279	Linear discriminant analysis (LDA) using blood cell subpopulations separates patients according to
280	PFS
281	We analyzed the AUC of cell counts (CD4+ and CD8+ T-cells, B-cells, CD56+CD3- NK-cells, eosinophils,
282	neutrophils, and the NLR) at the RTend to C.3 interval as predictor variables for PFS (response
283	variable), defined in 3 groups: PFS<6 mo, \geq 6<12 mo, and \geq 12 mo.
284	Discriminant markers for PFS≥12 mo (green area) were the AUCs of CD4+ T-cells, and CD56+ NK-cells
285	(Fig. 5, Fig. S5). By these markers, 6 of 9 patients of the PFS≥12 mo group were correctly separated
286	from the other PFS groups. Patients with intermediate PFS (\geq 6<12 mo) (grey area) were
287	discriminated by AUCs of B-cells and NLR, with four of five individuals of this group separated
288	correctly. The mean of prediction as a measure for accuracy was 0.947 for linear discriminant
289	analysis.



290

Fig. 5 Linear discriminant analysis group plot (response variable PFS, predictor variables were AUCs of the interval RTend C.3 of CD4+T-cells, CD8+T-cells, B-cells, NK-cells, eosinophils, neutrophils, and NLR). Mean as a measure for accuracy was
 0.947. The length and direction of the arrows indicate how well the parameter differentiates this group from the others.

294

295 Variation in IL-6 concentration is correlated with PFS

200 11 0 14 4	www.inflowers.org	الاصطلاح مسايل مسايرهم	مصلي من من المر		in in marker income	مثلم مرميرة المرارم
296 IL-61S a	pro-inflammatory	cytokine that	plays an im	portant role	in innate imr	nunity and is

- 297 upregulated in sepsis [6], after trauma [7], and medical treatment, e.g. surgery [8]. Basal IL-6 levels
- highly vary inter-individually [9], thus a comparison of absolute values for IL-6 across individuals is
- 299 difficult to interpret. We focused on the intra-individual variation of IL-6 concentrations (pg/ml) over
- 300 at least 3 consecutive timepoints, starting at RTend until C.3 as a clinically sensible interval for
- 301 survival prediction. The standard deviation of the IL-6 concentrations (pg/ml) during this interval (n=4
- 302 blood samples each patient) was used as a measure of variation of the IL-6 level.



303

Fig. 6 Standard deviation (SD) of IL-6 concentration from RTend-C.3 according to PFS groups (box plots showing median,

305 min and max); Student's T test, * p<0.05, ** p<0.01.

306

307 The favorable survival group had a median standard deviation (RTend-C.3) of 2.5 (range 0.7-6.6), the

308 poor survival group 22.9 (range 2.3-175.7), and the intermediate group 8.8 (range 4.0-12.3). Thus,

309 the IL-6 variation after RTend was significantly lower for the favorable PFS group and this significantly

310 correlated with PFS (p=0.007, Fig. 6).

311

312 Discussion

313 In this prospective explorative study, we evaluated the dynamics of defined peripheral leukocyte

314 subsets in patients with inoperable stage III NSCLC during primary treatment and follow-up with the

aim to identify peripheral T-cell subsets that may predict treatment outcome, especially PFS.

- Our analysis provides evidence that ALC expansion after the end of definitive RT or cCRT until 6 mo
- 317 afterwards is significantly associated with treatment efficacy. Increase of AC in CD3+ T-cells, CD8+
- 318 cytotoxic T-cells, and NK-cells had the most pronounced effect and was associated with favorable

319 PFS, whereas significant increase in B-cell counts had a less apparent positive association with PFS

320 and eosinophils and CD4+ T-cell counts had no association.

321 ALC before treatment (A.1) or at any other single timepoint did not reveal a correlation with PFS (Fig.

322 1). There was no significant correlation between ALC at six months after RTend and treatment

323 regimen (data not shown).

324 Comparable to findings of previously published studies [10], [11], [12], [13], all patients in this study 325 experienced moderate to severe lymphocytopenia during RT (A.2-RTend) with the nadir at the end of 326 radiotherapy. Most of our patients recovered from lymphocytopenia within the following 3 (C.2) to 6 327 (C.3) mo. Some (4 of 16 at C.3) had persistently low cell counts (Fig. 1), which correlated with poor 328 disease control with PFS less than 6 mo (Fig. 3). An earlier study [14] found an association between 329 severe lymphocytopenia (<500 cells/µl) and reduced OS (HR 1.70, p=0.17). Similar evidence was 330 observed in glioblastoma [15], cervical cancer [16] and in seminoma [17]. This is comparable to what 331 we see in this study, where patients with continuously low ALC had poor PFS and OS (Fig. S3c,d). 332 In our study patients had favorable PFS and OS when treated with cCRT+ICI compared to cCRT alone 333 (Fig. S3e,f). In a comparable investigation, Jing et al. [18] compared NSCLC patients who received 334 cCRT with those who received additionally maintenance treatment with durvalumab. They found a 335 significant increase in PFS in the durvalumab subgroup alongside with a significant correlation 336 between lymphocytopenia and PFS/OS. Jing et al. observed no statistically significant evidence that 337 patients with lymphocytopenia benefited from durvalumab in terms of improved overall survival. 338 However, the authors focused on severe lymphocytopenia with a cell count of less than 0.23 Gcells/L 339 $(230 \text{ cells}/\mu)$. Additional factors may play a role when ALC is extremely low. Our cohort was small 340 and only five patients had very low ALC at the end of radiation. Of these patients, two received RT, 341 one cCRT, and two received cCRT+ICI. Two cCRT+ICI patients showed a strong recovery of cell counts 342 together with favorable PFS (\geq 23 mo). Interestingly, Cho et al. [12] postulated that patients with

343 severe lymphocytopenia may benefit most from additional ICI because a fresh and immunological

344 potent lymphocyte population may arise from a depleted lymphocyte reservoir.

- 345 The timeperiod following end of RT is considered to be significant since processes involving
- immunogenicity take place that play a role in durable immune activation and tumor rejection [19],
- 347 [20]. In this study, we focused on the 6-mo period of RTend-C.3 and refer to it as a crucial recovery
- 348 phase. Considering the different lymphocyte subtypes (Fig. 2), we identified that an early increase in
- absolute counts after RT of total CD3+ T-cells and CD8+ T-cells was predictive of favorable PFS.
- 350 Interestingly, Belka et al. [17] found that CD8+ T-cells recovered significantly faster than CD4+ T-cells
- after end of radiation treatment in patients with seminoma. In head and neck cancer, a gradual
- increase in CD8+ T-cells over 6 mo after radiotherapy was observed for non-recurrent patients [21].

353 This supports our finding that an early increase in CD8+ T-cells in peripheral blood may be useful to

354 predict favorable PFS. Kim et al. [22] reported on increasing frequency of Ki67+ cells within CD8+ PD-

355 1+ T-cells in patients with locally advanced NSCLC during cCRT peaking at the last week during

356 therapy followed by a decline 1-mo post-cCRT. These cells acquired a senescence phenotype.

357 Although we did not include the Ki67 marker in this study we did not see a decline of CD8+ T-cells but

358 rather more CD8+ T-cells in absolute counts from C.1.

359

360 We assumed that the dynamic changes of the cell counts may be meaningful for patient survival.

361 Evidence that T-cell recovery is important was shown in a study of melanoma patients by Huang et al.

362 [20]. They found that a CD8+ Ki67+ T-cell subpopulation positively correlated with clinical outcome

363 when it peaked at a given early timepoint after therapy begin and subsequently decreased. To reflect

- 364 the dynamic changes in absolute cell count in given subpopulations during the recovery interval of
- 365 Rtend-C.3, we calculate the AUC between four consecutive timepoints within 6 mo after RT (RTend-

366 C.1-C.2-C.3). This new approach can depict a broader picture of cellular dynamics in peripheral blood

- 367 than the stepwise comparison of single timepoints. We identified that total lymphocytes and
- 368 neutrophils, CD3+ T-cells, B-cells and NK-cells recover significantly faster and reach significantly

369 higher AUC in patients with favorable PFS≥12 mo. Considering the T-cell subsets in this study, the 370 prediction of long-term survival using this AUC method was statistically significant with the CD4+ but 371 not with CD8+ T-cells. We additionally used LDA as a classical approach in pattern recognition to 372 define the cell subsets that contribute most to favorable outcome during the recovery phase [23]. A 373 high value in AUC of CD4+ T-cells and NK-cells after RT end was found to correlate with a PFS≥12 mo. 374 High AUC of CD4+T-cells and NK-cells as well as addition of ICI contributed mostly to favorable PFS, 375 and a trend of fewer local recurrences in these patients was detected. 376 We also analyzed IL-6 plasma concentrations during and after treatment. In in-vitro experiments 377 using human NSCLC cancer cell lines as well as mouse models, Yamaji et al. [24] found an association 378 between IL-6 and tumor proliferation. The pro-inflammatory cytokine IL-6 has predictive potential of 379 severity in a variety of diseases, e.g. heart disease [25], pneumonia [26]. Absolute IL-6 values are 380 challenging to compare across individuals because of interindividual differences as well as 381 dependency on gender, sex, and age [27]. Therefore, we interrogated the intra-individual dynamics 382 of IL-6 within a 6-mo period following RT/cCRT using the standard deviation as a measure for the 383 magnitude of this variation. We found a strong negative correlation of IL-6 variation with PFS, which 384 is consistent with the findings of Yamaji et al. [24]. 385

386 The current study has limitations. The study encompassed only a small number of patients (n=20) 387 distributed over different treatment regimes. LDA may be problematic when used with small sample 388 numbers [28]. To mitigate this issue, we interrogated a potential association with clinical benefit (OS, 389 PFS) by various means including comparisons of single markers at individual timepoints or time 390 intervals, as well as multi-parametric comparisons using unsupervised clustering and discriminatory 391 analysis. Despite its limitations, our study has its value as it was conducted prospectively, and 392 samples were collected longitudinally at multiple timepoints to characterize the recovery phase after 393 RT. The results can be considered as a hypothesis to be tested in follow-up studies. If confirmed, the

- treatment, are immediately amenable to clinical practice. A follow-up study is in progress including
- 396 40 inoperable stage III NSCLC patients [29].

397

- 398 Conclusions
- 399 The present findings suggest that two parameters, which are commonly assessed in clinical routine,
- 400 can be used to predict patient outcome. An early increase in CD8+ T cell lymphocyte count and low
- 401 standard deviation in IL-6 plasma concentration are significantly correlated to patients with
- 402 favorable, respectively poor outcome (PFS) after definitive therapy independent of treatment
- 403 scheme. If confirmed, the two identified parameters are immediately amennable to clinical practice.

404

405

406

- 407 **Declarations**
- 408 Ethics approval and consent to participate
- 409 The study was approved by the Human Ethics Committee of the Ludwig-Maximilians-University of
- 410 Munich reference no. 17-632 and conducted in accordance with the Declaration of Helsinki. Patients
- 411 were included into the study after informed consent.

- 413 Acknowledgements
- 414 We thank patients and their families, the clinicians and staff member of the LMU hospital, and
- 415 colleagues at the Asklepios Fachkliniken München-Gauting.
- 416 For excellent support, we thank Anna Herbstritt, Barbara Mosetter, and Adam Slusarski.

419 References

420	1.	Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG,
421		Groome P, Mitchell A, Bolejack V, et al: The IASLC Lung Cancer Staging Project: Proposals for
422		Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM
423		Classification for Lung Cancer. J Thorac Oncol 2016, 11:39-51.
424	2.	Ribas A, Wolchok JD: Cancer immunotherapy using checkpoint blockade. Science 2018,
425		359: 1350-1355.
426	3.	Page DB, Postow MA, Callahan MK, Allison JP, Wolchok JD: Immune modulation in cancer
427		with antibodies. Annu Rev Med 2014, 65:185-202.
428	4.	Li S, Zhang C, Pang G, Wang P: Emerging Blood-Based Biomarkers for Predicting Response to
429		Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer. Front Immunol 2020,
430		11 :603157.
431	5.	Hammer O: PAST: Paleontological statistics software package for education and data
432		analysis. Palaeontologia Electronica 2001, 4 .
433	6.	Hack CE, De Groot ER, Felt-Bersma RJ, Nuijens JH, Strack Van Schijndel RJ, Eerenberg-Belmer
434		AJ, Thijs LG, Aarden LA: Increased plasma levels of interleukin-6 in sepsis. Blood 1989,
435		74: 1704-1710.
436	7.	Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O'Keefe
437		G, Sperry J, et al: Early elevation in random plasma IL-6 after severe injury is associated
438		with development of organ failure. Shock 2010, 34:346-351.
439	8.	Cheng E, Shi Q, Shields AF, Nixon AB, Shergill AP, Ma C, Guthrie KA, Couture F, Kuebler P,
440		Kumar P, et al: Association of Inflammatory Biomarkers With Survival Among Patients With
441		Stage III Colon Cancer. JAMA Oncol 2023.
442	9.	Said EA, Al-Reesi I, Al-Shizawi N, Jaju S, Al-Balushi MS, Koh CY, Al-Jabri AA, Jeyaseelan L:
443		Defining IL-6 levels in healthy individuals: A meta-analysis. J Med Virol 2021, 93:3915-3924.

444	10.	Zhang J, Huang SH, Li H, Li Y, Chen XL, Zhang WQ, Chen HG, Gu LI: Preoperative lymphocyte
445		count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer.
446		Med Oncol 2013, 30: 352.
447	11.	Chen NB, Xiong M, Zhou R, Zhou Y, Qiu B, Luo YF, Zhou S, Chu C, Li QW, Wang B, et al: CT
448		radiomics-based long-term survival prediction for locally advanced non-small cell lung
449		cancer patients treated with concurrent chemoradiotherapy using features from tumor and
450		tumor organismal environment. Radiat Oncol 2022, 17:184.
451	12.	Cho Y, Kim Y, Chamseddine I, Lee WH, Kim HR, Lee IJ, Hong MH, Cho BC, Lee CG, Cho S, et al:
452		Lymphocyte dynamics during and after chemo-radiation correlate to dose and outcome in
453		stage III NSCLC patients undergoing maintenance immunotherapy. Radiother Oncol 2022,
454		168: 1-7.
455	13.	Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael RA, Hong DS, Komaki R, Welsh JW:
456		Lymphopenia association with gross tumor volume and lung V5 and its effects on non-
457		small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys 2014, 89:1084-1091.
458	14.	Campian JL, Ye X, Brock M, Grossman SA: Treatment-related lymphopenia in patients with
459		stage III non-small-cell lung cancer. Cancer Invest 2013, 31:183-188.
460	15.	Mohan R, Liu AY, Brown PD, Mahajan A, Dinh J, Chung C, McAvoy S, McAleer MF, Lin SH, Li J,
461		et al: Proton therapy reduces the likelihood of high-grade radiation-induced lymphopenia
462		in glioblastoma patients: phase II randomized study of protons vs photons. Neuro Oncol
463		2021, 23: 284-294.
464	16.	van Meir H, Nout RA, Welters MJ, Loof NM, de Kam ML, van Ham JJ, Samuels S, Kenter GG,
465		Cohen AF, Melief CJ, et al: Impact of (chemo)radiotherapy on immune cell composition and
466		function in cervical cancer patients. Oncoimmunology 2017, 6:e1267095.
467	17.	Belka C, Ottinger H, Kreuzfelder E, Weinmann M, Lindemann M, Lepple-Wienhues A, Budach
468		W, Grosse-Wilde H, Bamberg M: Impact of localized radiotherapy on blood immune cells
469		counts and function in humans. Radiother Oncol 1999, 50:199-204.

470	18.	Jing W, Xu T, Wu L, Lopez PB, Grassberger C, Ellsworth SG, Mohan R, Hobbs BP,
471		Blumenschein GR, Tu J, et al: Severe Radiation-Induced Lymphopenia Attenuates the
472		Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep
473		2022, 3 :100391.
474	19.	Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC: Ionizing radiation
475		inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat
476		Oncol Biol Phys 2004, 58: 862-870.
477	20.	Huang AC, Postow MA, Orlowski RJ, Mick R, Bengsch B, Manne S, Xu W, Harmon S, Giles JR,
478		Wenz B, et al: T-cell invigoration to tumour burden ratio associated with anti-PD-1
479		response. Nature 2017, 545:60-65.
480	21.	Niu M, Combs SE, Linge A, Krause M, Baumann M, Lohaus F, Ebert N, Tinhofer I, Budach V,
481		von der Grun J, et al: Comparison of the composition of lymphocyte subpopulations in non-
482		relapse and relapse patients with squamous cell carcinoma of the head and neck before,
483		during radiochemotherapy and in the follow-up period: a multicenter prospective study of
484		the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). Radiat Oncol 2021,
485		16 :141.
486	22.	Kim KH, Pyo H, Lee H, Oh D, Noh JM, Ahn YC, Yoon HI, Moon H, Lee J, Park S, et al: Dynamics
487		of Circulating Immune Cells During Chemoradiotherapy in Patients with Non-Small Cell
488		Lung Cancer Support Earlier Administration of Anti-PD-1/PD-L1 Therapy. Int J Radiat Oncol
489		<i>Biol Phys</i> 2022, 113: 415-425.
490	23.	Ye J, Ji S: Discriminant analysis for dimensionality reduction: An overview of recent
491		developments; in Biometrics: Theory, Methods, and Applications. Wiley IEEE Press, New York;
492		2009.
493	24.	Yamaji H, lizasa T, Koh E, Suzuki M, Otsuji M, Chang H, Motohashi S, Yokoi S, Hiroshima K,
494		Tagawa M, et al: Correlation between interleukin 6 production and tumor proliferation in
495		non-small cell lung cancer. Cancer Immunol Immunother 2004, 53:786-792.

496	25.	Zhang WR,	Garg AX, C	Coca SG,	Devereaux PJ,	Eikelboom J	, Kavsak P,	McArthur E,	Thiessen-
-----	-----	-----------	------------	----------	---------------	-------------	-------------	-------------	-----------

- 497 Philbrook H, Shortt C, Shlipak M, et al: Plasma IL-6 and IL-10 Concentrations Predict AKI and
- 498 Long-Term Mortality in Adults after Cardiac Surgery. J Am Soc Nephrol 2015, 26:3123-3132.
- 499 26. Woiciechowsky C, Schoning B, Cobanov J, Lanksch WR, Volk HD, Docke WD: Early IL-6 plasma
- 500 concentrations correlate with severity of brain injury and pneumonia in brain-injured
- 501 **patients.** *J Trauma* 2002, **52**:339-345.
- 502 27. Wei J, Xu H, Davies JL, Hemmings GP: Increase of plasma IL-6 concentration with age in
 503 healthy subjects. *Life Sci* 1992, 51:1953-1956.
- 504 28. Tharwat A, Gaber T, Ibrahim A, Hassanien AE: Linear discriminant analysis: A detailed
- 505 **tutorial.** *Ai Communications* 2017, **30**:169-190.
- 506 29. Kasmann L, Taugner J, Eze C, Nieto A, Pelikan C, Florsch B, Kenndoff S, Hofer TP, Nossner E,
- 507 Schulz C, et al: Prospective evaluation of immunological, molecular-genetic, image-based
- and microbial analyses to characterize tumor response and control in patients with
- 509 unresectable stage III NSCLC treated with concurrent chemoradiotherapy followed by
- 510 consolidation therapy with durvalumab (PRECISION): protocol for a prospective
- 511 **longitudinal biomarker study.** *Transl Lung Cancer Res* 2022, **11**:1503-1509.